Objective: Digoxin is widely used in controlling ventricular rhythm in atrial fibrillation and heart failure. Therapeutic serum levels of digoxin are 0.5-2 ng/mL. Toxicity may occur after acute accidental or suicidal ingestion or with chronic therapy. In this study, we aimed to determine the frequency of high serum digoxin levels and its association with factors, such as age, gender, and comorbidities. Methods: A 3-year (January 2009-December 2011) cross-sectional study was performed, and a total of 2480 patients who were hospitalized or visited the outpatient clinics were included in this study. Details of serum digoxin levels, age, gender, and comorbidities were retrospectively retrieved from the laboratory data system. Results: The mean (range) age was 71.33±12.24 (min. 18, max. 97) years and 74.1% of the patients were elderly (age≥65). The rate of high serum digoxin levels was found to be 17.8% in our study population (n=439). A total of 87.9% of the patients with high serum digoxin levels were elderly and 71% of them were females. The most common symptoms and comorbidities in patients who had serum digoxin levels >2 ng/mL were dyspnea and vomiting in females, heart failure and chest pain in males. Conclusion: This study shows that higher serum digoxin levels are associated with older age and female gender. Increased awareness of medication safety in geriatric population is important. Because of altered pharmacokinetics of digoxin with age, therapeutic monitoring is needed.
Introduction
Digoxin is a drug that has been used in cardiovascular treatment for many years. It is known to be particularly effective in heart failure and atrial fibrillation (1) . In recent years, the clinical use of alternative drugs (such as beta blockers, angiotensin receptor blockers, and angiotensin converting enzyme inhibitors) and the effectiveness of digoxin as the first choice have been controversial (2) (3) (4) . Furthermore, in some observational studies, it has been suggested that digoxin can increase mortality in patients (5, 6) . It is known that digoxin is a drug with a narrow therapeutic range, and therefore, it can lead to mortality and hospitalization in patients, in association with the factors that will affect the metabolism of this drug (7) . For this reason, serum digoxin levels are measured in order to detect or prevent possible digoxin intoxication.
Digoxin intoxication seems to be one of the main reasons for the restriction of digoxin usage in treatment; moreover, this intoxication can be life-threatening. Digoxin intoxication is one of the most common causes of admission to the emergency unit (7) . Therefore, it is important to approach and evaluate the clinical picture accurately. In addition to the measurement of serum digoxin levels, various factors that can cause digoxin intoxication or increased serum levels of the drug should be investigated. The results of epidemiological studies on digoxin toxicity and mortality and morbidity of diseases that are treated with digoxin are different (5, 8, 9) . In this study, we aimed to investigate the relationship of serum digoxin levels, which were measured in the biochemistry laboratory of our hospital, with age, gender, and findings and diagnoses at admission.
Methods
This study was a descriptive and retrospective study. The files of patients whose serum digoxin levels were measured in the Biochemistry Laboratory in İzmir Atatürk Education and Research Hospital between January 2009 and December 2011 were evaluated retrospectively. Serum digoxin levels >2 ng/ mL were evaluated to be "high." The measured values were compared with age, gender, and diagnoses. Moreover, the distribution of comorbid diseases in patients with high serum digoxin levels was examined according to age and gender.
The diagnoses of diseases were coded in accordance with the International Classification of Diseases-10 at the time of measurement. All patients in the study were ≥18 years of age, and all patients whose serum digoxin levels were measured within the above mentioned dates were included in the study regardless of gender because of the sectional characteristic of the study. The results of the samples re-requested from the same patient were not evaluated. Serum digoxin levels were measured using the immunoturbidimetric method (Architect c16000; Abbott, Wiesbaden, Germany). The ethical approval for the study was received from İzmir Katip Çelebi University, Ethics Committee for Non-Invasive Clinical Research (date, 02.06.2016; decision number, 150).
Statistical analysis
For statistical analysis, Statistical Package for the Social Sciences 18.0 version (SPSS, Chicago, IL, USA) software was used. The obtained data were presented as numbers, percentages, and means±standard deviations. For categorical vari-ables, the differences between the groups were evaluated with the Chi-square and Fisher's Chi-square tests and a value of p<0.05 was accepted to be significant.
Results
The results of 2,480 patients between January 2009 and December 2011 were found and examined. Of them, 1,550 were female and 930 were male. In the evaluation of the age groups of patients whose serum digoxin levels were requested, patients ≥65 years of age (n=1,839, 74.1%) were found to be more common. The mean age was recorded as 71.33±12.24 (minimum, 18; maximum, 97) years. The distribution of the results of the patients is given in Figure 1 in detail.
Serum digoxin levels of 2,480 patients were examined and were found to be in the therapeutic range to a large extent (41.23%). Serum digoxin levels of 372 (15%) patients were very low (<0.19 ng/mL) and those of 24 (1%) patients were >5 ng/mL. The number of patients with high serum digoxin level was 439 (17.8%) ( Table 1 ).
In the measurement analysis according to years, 740 of samples belonging to a total of 2,480 patients were found to be evaluated in 2009, 1,024 in 2010, and 716 in 2011. High serum digoxin levels were observed in 14.3% of the measurements in 2009, in 18.5% in 2010, and in 1.9% in 2011.
Further, 87.9% of patients with high serum digoxin levels were ≥65 years. Moreover, 312 (71%) of 439 patients were female, and 127 (29%) were male. In the evaluation of serum digoxin levels, shown in Table 2 , in female and male patients and in patients ≥ or <65 years of age, the values did not display a significant distribution in any range. Besides that, a statistical significance was detected in the distribution of patients according to gender (female or not) and age groups (≥65 years of age or not) (p<0.01 for both parameters).
The referrals to our biochemistry laboratory for the measurement of serum digoxin levels were mostly from the emergency unit (1,407 patients, 56.7%), followed by the cardiology clinic (250 patients, 10%), cardiology outpatient clinic (173 The detailed distribution of the diagnoses accompanying high serum digoxin levels in patients ≥65 years of age is given in Table 4 according to age groups. Nausea/vomiting, cerebrovascular disorder, congestive heart failure, pneumonia, atherosclerotic heart disease, dizziness, and left ventricular failure were not included among the diagnoses of patients in the age range of 65-69 years. Conversely, cerebrovascular disorder, congestive heart failure, and atherosclerotic heart disease were observed to become more common for patients in the age range of 80-89 years.
Discussion
Digoxin is one of the oldest drugs used in the clinical treatment of heart diseases (9) . It is primarily used for controlling heart rate in the treatment of atrial fibrillation and congestive heart failure. The measurement of the serum levels of this drug, which has a narrow therapeutic range and can require long-term usage, for control or in cases of suspicion of intoxication can guide doctors, particularly, in patients with clinical findings. Only high serum digoxin level is not enough to establish the diagnosis of digoxin intoxication because distri- 
Figure 1. Distribution of serum digoxin levels in the age groups
Patients whose serum digoxin levels were measured (n) 18 bution volume of digoxin is quite wide, and serum levels do not give information about the distribution of digoxin in the tissues (10) .
Epidemiological studies on atrial fibrillation and congestive heart failure demonstrate that being male and of advanced age are risk factors (11, 12) . In addition, the risk of stroke and mortality in atrial fibrillation is higher in female patients than in male patients, and high blood pressure and heart failure with preserved ejection fraction are more common, particularly in older female patients than in male patients (13, 14) . According to the results of our study, the majority of patients whose serum digoxin measurements were requested were female, and the number of female patients was 1.66 times higher than that of male patients. Approximately 3 of 4 patients were ≥65 years of age. In conclusion, most of the patients whose samples were evaluated were elderly and female. This supports the hypothesis that heart diseases requiring the use of digoxin become complicated in elderly female patients more frequently. As shown in Figure 1 , the measurement of serum digoxin levels was performed mostly for patients in the age group of 75-84 years, and high levels were found in patients in this age group at a rate higher than that in other groups.
Serum digoxin levels were >2 ng/mL in 439 (17.8%) of 2,480 patients whose levels were measured. Further, 41.3% of the measurements were recorded to be in the therapeutic range of 0.8-2 ng/mL. In our study, the presence of a significant relationship between high serum digoxin levels and female gender and advanced age can be attributed to the fact that most of patients whose levels were measured were female and of advanced age. It was reported in previous studies that the rate of hospitalization was higher in elderly female patients receiving digoxin therapy compared to that in other patients (15) .
In the comparison of time intervals in which serum digoxin levels were measured (2009-2011), an increase was detected in 2010 compared to that in the other years. The detection rates of high serum digoxin levels have increased slightly over the years. Although some studies on this subject have suggested a decrease in digoxin toxicity cases in the 2000s (16, 17) , recent studies have revealed an increase in digoxin toxicity cases with high serum digoxin levels, which is similar to the results of our study (18) .
Most of the admissions and high measurement values were of patients visiting the emergency unit. A significant proportion of them were from the cardiology clinic, outpatient clinic, and coronary intensive care unit. In parallel to these results, the accompanying diagnoses were observed to be mostly poisoning findings (dyspnea, chest pain, nausea/vomiting, bradycardia, palpitation, fatigue, and abdominal pain), heart failure, and atrial fibrillation. Vomiting, abdominal pain, chest pain, dyspnea, and sinus bradycardia were observed frequently in acute intoxication by digoxin. In addition, ventricular tachycardia or fibrillation can develop. In chronic intoxication cases, visual impairments, fatigue, sinus bradycardia, atrial fibrillation with retarded ventricular response, or ventricular arrhythmia (ventricular tachycardia and ventricular fibrillation) can occur (19) . Dyspnea and heart failure are the most frequently reported diagnoses in female and male patients, respectively. This suggests that digoxin toxicity is more symptomatic in female patients, and the known diagnosis of heart failure in male patients has existed previously.
The most important limitation of our study is that other parameters, particularly serum creatinine, which could affect the pharmacokinetics of digoxin, were not included in the measurement analysis because they could cause remarkable changes in the sampling size. Conversely, the evaluation of results obtained from retrospectively reliable measurements in a large sample is valuable for revealing statistical significance.
Conclusion
In this study, serum digoxin levels analyzed in our laboratory between 2009 and 2011 were evaluated based on the value of 2 ng/mL, which is the upper limit of the known therapeutic concentration range. The commonly used range for the measurement of serum digoxin levels is 0.8-2.0 ng/mL. This concentration range can be used for evaluating digoxin toxicity with clinical findings, rather than the drug effectiveness (2, 20) . Retrospective analyses performed in the 2000s have revealed that mortality increases in patients with serum digoxin levels >1 ng/mL and decreases in patients with levels <0.8 ng/mL (21, 22) . In some clinical guidelines that have recently been published in Europe and America, there are some views about changing the therapeutic serum digoxin levels to 0.5-1.0 ng/mL (23, 24) , which supports the results of the above mentioned studies. Despite agreement on this point, the value of 2.0 ng/mL is still used as the upper limit for the measurement of digoxin in many laboratories (25) .
To target low drug concentrations can have negative outcomes, such as subtherapeutic drug concentrations. However, serum digoxin levels can provide information only in the evaluation of toxicity with clinical findings. Therefore, evaluation of the clinical picture together with other factors such as gender, age, and accompanying findings and diseases will be the most effective.
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